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Quality of life impact and recovery
after ureteroscopy and stent insertion: insights
from daily surveys in STENTS
Jonathan D. Harper1*†, Alana C. Desai2†, Jodi A. Antonelli3, Gregory E. Tasian4, Justin B. Ziemba5,
Hussein R. Al‑Khalidi6, H. Henry Lai2,7, Naim M. Maalouf8, Peter P. Reese9,10, Hunter B. Wessells1, Ziya Kirkali11,
Charles D. Scales Jr.12 and NIDDK Urinary Stone Disease Research Network (USDRN)

Abstract
Background: Our objective was to describe day-to-day evolution and variations in patient-reported stent-associated
symptoms (SAS) in the STudy to Enhance uNderstanding of sTent-associated Symptoms (STENTS), a prospective mul‑
ticenter observational cohort study, using multiple instruments with conceptual overlap in various domains.
Methods: In a nested cohort of the STENTS study, the initial 40 participants having unilateral ureteroscopy (URS)
and stent placement underwent daily assessment of self-reported measures using the Brief Pain Inventory short
form, Patient-Reported Outcome Measurement Information System measures for pain severity and pain interference,
the Urinary Score of the Ureteral Stent Symptom Questionnaire, and Symptoms of Lower Urinary Tract Dysfunction
Research Network Symptom Index. Pain intensity, pain interference, urinary symptoms, and bother were obtained
preoperatively, daily until stent removal, and at postoperative day (POD) 30.
Results: The median age was 44 years (IQR 29,58), and 53% were female. The size of the dominant stone was 7.5 mm
(IQR 5,11), and 50% were located in the kidney. There was consistency among instruments assessing similar con‑
cepts. Pain intensity and urinary symptoms increased from baseline to POD 1 with apparent peaks in the first 2 days,
remained elevated with stent in situ, and varied widely among individuals. Interference due to pain, and bother due
to urinary symptoms, likewise demonstrated high individual variability.
Conclusions: This first study investigating daily SAS allows for a more in-depth look at the lived experience after URS
and the impact on quality of life. Different instruments measuring pain intensity, pain interference, and urinary symp‑
toms produced consistent assessments of patients’ experiences. The overall daily stability of pain and urinary symp‑
toms after URS was also marked by high patient-level variation, suggesting an opportunity to identify characteristics
associated with severe SAS after URS.
Keywords: Urinary stone disease, Ureteroscopy, Ureteral stent, Stent-associated symptoms
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Introduction
Patients who receive a ureteral stent often experience
debilitating symptoms, including pain, urinary urgency
and frequency, hematuria, and incontinence. Researchers
have struggled to understand and predict the severity and
range of stent-associated symptoms (SAS) following ureteroscopy (URS) for stone disease. While most patients
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will have some degree of SAS, it is unknown who will suffer from severe symptoms that significantly affect quality of life. Furthermore, a clear understanding of the daily
variation of SAS after URS remains elusive; having this
information is critical to patient counseling, serving as a
building block for stent-related research, and employing
strategies to mitigate these symptoms.
Investigation of SAS is a research priority as URS has
become the most common procedure performed for
renal and ureteral stones, and stents are used in most
cases [1–3]. Contrary to popular belief, some studies
have shown that stents are not associated with increased
hospital returns [4] and may actually reduce unplanned
visits [3, 5, 6]. Therefore, despite SAS, ureteral stents continue to play an important role in reducing complications
such as urinary obstruction, and may slightly reduce ureteral stricture formation [5]. Given the limited insight
into drivers of SAS and lack of characterization of the
patient’s daily experience after URS, the Urinary Stone
Disease Research Network is conducting the STudy to
Enhance uNderstanding of sTent-associated Symptoms
(STENTS), a prospective observational cohort study.
A key consideration for improving understanding of
SAS is assessment of patient-reported symptoms. Patientreported measures provide important information about
the impact of a condition and/or treatment from the
patient’s perspective. Within the overall STENTS study,
an initial nested cohort study was designed as a unique
opportunity to gain a better understanding of patients’
daily experiences after URS for stone treatment. Our
goal was to determine the trajectory of day-to-day variations in pain intensity, pain interference, urinary symptoms, and bother, identify a peak day of symptoms, and
provide guidance for future studies in choosing outcome
measures.

Materials and methods
Study design and nested cohort

STENTS is a multi-institutional prospective observational cohort study of individuals undergoing URS and
ureteral stent placement for treatment of a ureteral or
renal stone. A complete description of the STENTS protocol has been published [7]. The initial 40 participants
made up the nested cohort. A minimum number of participants based on age and gender were prespecified to
ensure inclusion of specific age and gender groups in
this nested cohort: the minima required were 8 individuals aged 12–25, 12 males aged > 25 years, and 12 females
aged > 25 years.
In brief, the nested cohort study was designed such
that participants would complete all study procedures
performed in the subsequent larger STENTS observational cohort. Unique to the nested cohort, these 40
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participants completed daily questionnaires that assessed
pain intensity, pain interference, urinary symptoms, and
bother, and also participated in a semi-structured interview to further characterize the patient experience. The
prespecified objectives of the nested cohort were to generate knowledge about the daily variation of pain intensity, pain interference, urinary symptoms, and bother;
identify a peak day of symptoms; and evaluate overlap
in experience assessment among the instruments. These
analyses informed the selection of instruments and the
timing of their administration for the main STENTS
cohort.
Study population

Individuals aged 12 and older with a planned unilateral
URS for stone treatment were recruited from four clinical
centers. All participants were prospectively enrolled after
institutional review board approval. Participants aged
17 and under provided their informed assent, and their
parents provided parental permission. Exclusion criteria
were an indwelling ureteral stent, receipt of a stent in the
preceding 60 days, concomitant shockwave lithotripsy
or percutaneous nephrolithotomy, conditions resulting
in neurogenic bladder dysfunction, anatomic urological
abnormality resulting in abnormal bladder sensation, or
renal transplantation; bedridden and vulnerable populations were also excluded.
Study procedures

Participants completed baseline questionnaires that
recorded individual characteristics, medical and stone
history, and medication use. Participants with a history of
a ureteral stent reported whether they had severe pain or
urinary symptoms with their prior stent. Intraoperative
data, including stone features, details of ureteral instrumentation, irrigation type, and stent characteristics, were
prospectively collected at the time of URS.
Patient experiences

All participants in the nested STENTS cohort were
administered the following questionnaires that assessed
pain, urinary symptoms, and the manner and degree to
which these symptoms impact the patient’s life (interference and bother): (1) the Brief Pain Inventory (BPI)
short form [8], which has been used in pain studies
widely, assessed pain intensity and pain interference;
(2) Patient-Reported Outcome Measurement Information System (PROMIS) [9] measures of pain intensity
and pain interference allowed for comparing scores
to population norms; (3) the Urinary Score of the Ureteral Stent Symptom Questionnaire (USSQ) [10], an
instrument developed for SAS over a 1-month recall
period, assessed urinary symptoms and bother; and (4)
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Symptoms of Lower Urinary Tract Dysfunction Research
Network Symptom Index (LURN SI-10) assessed urinary
symptoms and bother [11]. We intentionally administered questionnaires that assessed the same construct
in order to determine potential differences in the measured experience. We acknowledge that the USSQ covers other domains besides urinary symptoms, but given
the importance of characterizing pain intensity and pain
interference as accurately as possible, being able to compare to population norms, and our desire for a comprehensive body map that incudes genitalia, it was decided
to incorporate specific pain instruments that are used
in the broader community of medicine. This was after
several discussions with a multidisciplinary field including experts within pain medicine, pain psychology, and
psychometricians well versed in development of patient
reported outcome measures. Table 1 shows the instruments listed by SAS domain.
Data collection

Participants completed the above questionnaires preoperatively (baseline), on postoperative day (POD) 1, daily
until stent removal, including day of stent removal, and
30 days after stent removal (Table 1). Questionnaires
were self-administered and completed each day via electronic format, or paper copies if preferred. Participants
received an electronic link each day reminding them to
complete the forms.
Participants were contacted by study staff to record any
adverse events. Prescribed medications following surgery
were assessed using a medication diary. Finally, participants were asked about any health care utilization during
the 30 days following stent removal.
Statistical analysis

Data are summarized as medians (25th, 75th percentiles)
and means (SDs) for continuous variables and as counts
(percentages) for categorical variables. Due to multiple

Table 1 Self-reported measures used in the study by stentassociated symptoms domain
Instrument

BPI

Domain
Pain
Intensity

Pain
Interference

•

•

LURN SI-10
PROMIS
USSQ-U

•

Urinary
Symptoms

Urinary
Bother

•

•

•
•

•

BPI = Brief Pain Inventory; LURN SI-10 = Symptoms of Lower Urinary Tract
Dysfunction Research Network Symptom Index; PROMIS = Patient-Reported
Outcome Measurement Information System; USSQ-U = urinary score of the
Ureteral Stent Symptom Questionnaire

outcomes assessed at many time points and the small
sample size, we did not test for differences in symptom
severity across instruments or days. Summary statistics
of daily patient-reported symptoms were calculated, and
data are graphically depicted in box-and-whisker plots.
All statistical summary data were generated using SAS
statistical software version 9.4 (SAS Institute, Inc., Cary,
NC).

Results
Forty participants were included, comprising 9 individuals (3 male and 6 female) aged 12–25 years, 16 males
aged > 25 years, and 15 females aged > 25 years. The
median age was 44 years (IQR 29, 58), and 53% were
female. Over half (58%) of the participants had a prior
history of kidney stones. Of the 13 (33%) who had a ureteral stent in the past, 8 reported having severe pain and
6 reported having severe urinary symptoms with their
previous stent. Participant characteristics are listed in
Table 2, and intraoperative data are shown in Table 3.
Most participants had more than one stone treated, with
the dominant stone location evenly split between renal
Table 2 Participant characteristics at baseline
Characteristic
Sex: female

Participants (n = 40)
21 (53%)

Race
White

38 (95%)

Black

2 (5%)

Ethnicity: Hispanic/Latinx

3 (8%)

Age (years)
Median (IQR)

43.5 (28.5, 57.5)

Mean (SD)

43.1 (17.6)

Medical history
Depression

9 (23%)

Anxiety

8 (20%)

Mood disorder (other)

1 (3%)

Chronic pain condition
Previous stone history

7 (18%)
23 (58%)

Prior ureteroscopy

12 (30%)

Prior ureteral stent placement

13 (33%)

Severe pain with prior ureteral stent

8 (20%)

Severe urinary symptoms with prior ureteral
stent

6 (15%)

Medication use in past 30 days
Opioids

11 (28%)

NSAIDs

20 (50%)

Tamsulosin (or alpha blocker)

16 (40%)

Oxybutynin (or anticholinergic)

3 (8%)

Data shown are n (%) except where indicated. IQR = 25th, 75th percentiles;
SD = standard deviation; NSAIDs = nonsteroidal anti-inflammatory drugs
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Table 3 Intraoperative data
Variable

Participants (n = 40)

Side of treatment
Right

19 (48%)

Left

21 (52%)

Dominant stone size (renal, mm)
Median (IQR)

7.5 (5.0, 10.5)

Mean (SD)

7.5 (3.9)

Dominant stone size (ureteral, mm)
Median (IQR)

6.0 (5.0, 7.0)

Mean (SD)

6.2 (2.2)

Dominant stone location*
Renal

20 (50%)

Ureter (proximal)

7 (18%)

Ureter (distal)

13 (33%)

Number of stones treated (renal)
Median (IQR)

2 (1, 4)

Mean (SD)

5.6 (10.6)

Number of stones treated (ureteral)
Median (IQR)

1 (1, 2)

Mean (SD)

1.3 (0.5)

Operative time (min)
Median (IQR)
Mean (SD)

51 (36, 80)
59.1 (28.6)

Ureteroscopy time (min)
Median (IQR)

32.5 (20, 58.5)

Mean (SD)

40.1 (26.3)

Ureteroscope type*
Flexible

24 (60%)

Semirigid

7 (18%)

Both

9 (23%)

Ureteral access sheath use

19 (48%)

Basket extraction

33 (82%)

Irrigation
Manual

20 (50%)

Constant pressure

20 (50%)

Ureteral stent diameter
4.7 French

6 (15%)

6 French

34 (85%)

Ureteral stent length* (cm)
22

1 (3%)

24

18 (45%)

26

14 (35%)

28

5 (13%)

30

2 (5%)

Stent dwell time (days)
Median (IQR)
Mean (SD)

8 (6.5, 11)
10.1 (6.8)

*Note: percentages may not sum to 100 due to rounding
Data shown are n (%) except where indicated
IQR = 25th, 75th percentiles; SD = standard deviation

and ureteral. Stone sizes and location represent stones
treated during surgery.
Daily assessments of pain intensity, pain interference,
and urinary symptoms are displayed in Fig. 1. The percentage of completed questionnaires was very high, ranging from 84.6% to 98.8% completion on any given day.
Similar patterns in daily pain severity were seen using
both BPI and PROMIS. Pain intensity increased from
baseline to POD 1, remained elevated over the duration of the stent, and varied widely among individuals.
Median pain intensity scores were highest during the first
2 days after URS, with variable changes thereafter, but
remained persistently elevated compared to baseline.
Pain interference was noted to have a similar pattern
as pain intensity early in the postoperative course. Pain
interference scores increased versus baseline on POD 1,
with diminution over time, approaching baseline after
POD 5. As seen with pain intensity, there was also wide
inter-participant variation in reported interference due
to pain.
Urinary symptoms increased from baseline and
appeared to peak the day after surgery as measured by
both instruments. Urinary symptoms remained persistently elevated versus baseline, without substantial
decrease until after stent removal. Finally, bother due to
urinary symptoms increased and was most pronounced
immediately after URS. While median bother score mirrored the baseline value by POD 3, there was not definitive resolution until after stent removal. Wide variation
among individuals was again noted.

Discussion
This prospective cohort study was the first to measure the daily lived experiences of patients after URS for
stone disease. We found that there was wide variation
of self-reported pain and urinary symptoms daily, stent
symptoms peaked within the first 2 days after surgery
but remained elevated throughout stent dwell time,
and interference with daily activities secondary to pain
persisted longer compared to bother due to urinary
symptoms. We also found consistency among various
instruments that assessed similar concepts. These results
inform the selection of times at which stent symptoms
should be measured after URS and, given the variation
in symptoms among participants, reveal the importance of identifying characteristics that may help understand which patients are at greatest risk of severe stent
symptoms.
Most importantly, this study identified days of the
most intense SAS following URS. This information is
important in determining the days at which SAS should
be measured in research studies and also for counseling
patients about the expected experience after URS. We
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Fig. 1 Daily stent-associated symptoms in each domain measured with various instruments displayed in box and whisker plots. The range
(whiskers) is shown for each timepoint while the box represents the interquartile range. Circles depict mean values and the median values are
connected by a line: A BPI pain severity, B PROMIS pain intensity, C BPI pain interference, D PROMIS pain interference, E Urinary score of USSQ
(USSQ-U), F LURN SI-10 urinary symptoms

found that the magnitude of adverse symptoms occurred
within the first 2 days, a finding consistent among various instruments we used. This is in accord with a previous report by Lingeman and colleagues, who suggested
that symptoms peaked on the first day based on pain
medication use alone, although stent symptoms were not

formally measured until POD 4 [12]. Our findings from
daily assessment of SAS informed decisions for the main
STENTS cohort. We chose POD 1, 3, and 5 (in addition to day of stent removal and 30 days after removal)
in order to capture the peak symptoms and further analyze the trajectory of symptoms after URS. Our results
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indicate that there is no definitive time point in which
symptom assessment is not relevant to measure, since
the symptoms persist until stent removal.
The substantial variation in the reported pain intensity, pain interference, urinary symptoms, and urinary
bother among participants across our study period highlights the heterogeneity in the experience of individuals
undergoing URS for stones. To date, little is known about
risk factors for severe SAS, and further investigation
is needed. Younger age has been reported to be associated with more severe pain and unplanned hospital visits
[13–15]. Krambeck and colleagues, in a subset analysis,
reported decreased analgesic use in young males who had
a ketorolac-loaded stent, suggesting potential gender differences in stent tolerance [16]. In our study, while bother
due to urinary symptoms was most pronounced on POD
1 and 2, median bother was similar to baseline on subsequent days. In a recent study comparing stent designs,
Wiseman and colleagues postulated that the effect of
surgery on urinary symptoms may improve sooner than
pain [17]. A detailed investigation of the effects of patient
characteristics, stone factors, operative instrumentation, and medication use on SAS is the aim of the full
STENTS study, which will elucidate the potential causes
of SAS heterogeneity, identify patients at highest risk for
severe SAS, and may allow for the creation of a prediction model [7], all of which would be useful in counseling
patients in preemptive therapeutic decision-making and
identifying populations to study in future trials.
An important finding of this study is that there was
consistency observed among instruments that assessed
similar domains of the patient experience. We intentionally chose to perform a comprehensive assessment
of SAS using various instruments with conceptual
overlap. For example, pain intensity and pain interference were measured using the BPI and PROMIS. Pain
interference refers to pain that limits the patient’s ability to engage in daily activities, such as social-, work-,
or school-related functions. BPI has been used in painrelated studies widely, contains a complete body map,
and measures both the intensity of pain as well as the
interference of pain in one’s life. This is the first study,
to our knowledge, to use BPI following URS and stent
placement. Pain interference was seen to approach
baseline after several days as measured by the BPI.
The potential significance of this finding is unclear,
but there could be some element of adjustment to
SAS despite continuing to have pain, as measured by
pain severity. Pain intensity and interference were also
measured with individual PROMIS instruments, allowing for comparison with population norms. Recently,
PROMIS measures have been used to characterize
stone patients in various settings [18–20]. In our study,
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we noted consistency among instruments in ascertaining peak symptoms, the evolution of daily symptoms,
and the heterogeneity of the lived experiences following
URS and stent placement.
Our study is the first to determine the daily pattern
of pain intensity, pain interference, urinary symptoms,
and bother after URS with stent placement for the
entire postoperative period; however, the following limitations indicate opportunities to build on these findings. The large interindividual variation in symptoms
coupled with a relatively small sample size precluded
making multiple comparisons of the different domains
of pain intensity, pain interference, urinary symptoms,
and bother. These comparisons will be addressed in the
main STENTS cohort. Additionally, participants were
recruited from four clinical centers, and treatment of
SAS post-URS differed among urologists. Lastly, we did
not consider clustering by surgeon or institution.

Conclusion
In this first study measuring the daily lived experiences
of patients after URS for stone disease, daily experiences of pain intensity, pain interference, urinary symptoms, and bother were highly variable but seemed to
peak in the first 2 days and remained elevated while
the stent was in place. These findings may inform more
counseling of patients, shared decision making, and
serve as groundwork to facilitate additional research
for evaluating therapies and understanding mechanisms and risk factors for adverse experiences after
ureteroscopy.
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